INOVIO
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
660 W Germantown Pike Ste 110, Plymouth ...Phone Number
(267) 440-4200Website
www.inovio.comRevenue
-Stock Symbol
INOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About INOVIO
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline LifeRead more
INOVIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INOVIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if INOVIO has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when INOVIO launches new products
Check out if INOVIO is spiking on competitors!
Earning: See what the market has to say on INOVIO recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once INOVIO has new funding data
Click to see if INOVIO had a recent Job posting/layoffs
INOVIO, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at INOVIO
Recommended Actions
Find VP level buyers at INOVIO
Find more new buyers
Compare Similar Companies to INOVIO
Compare insights from companies similar to INOVIO, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.7B
201-500
Public
$1.1B
1998
RP
Rodney PlanchonManager, Quality Control & Chief Marketing Officer, External
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
INOVIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INOVIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INOVIO.
INOVIO financials insights
Gather financial insights about INOVIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$14M
Grant
$3.5M
2014
Stock Offering
$59.2M
2015
Stock Offering
$82.1M
Grant
$24M
2017
Stock Offering
$70.2M
2018
Grant
$56M
2019
Multiple Rounds
$98.9M
2020
Grant
$5M
INOVIO Tech Stack
A closer look at the technologies used by INOVIO
See more technologies
Most Recent Scoops
Earnings
INOVIO has reported a net loss of $6 million, or $0.07 per share basic and dilutive, for Q2 2026, compared to a net loss of $23.5 million, or $0.61 per share basic and dilutive, for Q2 2025, with the decrease primarily driven by a $13.9 million non-cash gain on fair value adjustment related to warrant liabilities for the three months ended June 30, 2026.
Earnings, Finance
Project
INOVIO has highlighted that INO-3107 does not require additional scoping and surgeries during the dosing window, differentiating it from papZimios, for which scoping and surgeries to remove papillomas are required prior to doses 3 and 4, with 83% of Phase I/II trial participants requiring at least one surgery during the dosing window.
Pharmaceuticals, Clinical Operations
Project
INOVIO has reported that INO-3107 demonstrated clinical efficacy in its Phase I/II trial, with the vast majority of patients experiencing a 50% to 100% reduction in surgery in year one and continued clinical improvement in year two, while also exhibiting a well-tolerated safety profile and a differentiated mechanism of action not impacted by pre-existing neutralizing antibodies or an immunosuppressive tumor microenvironment.
Medical Research, Pharmaceuticals, Clinical Operations
Earnings
INOVIO has reported operating expenses of $18.6 million for Q2 2026, a decrease of 19% compared to $23.1 million in Q2 2025, and reduced operating expenses by 16% for the first six months of 2026 compared to the same period last year, driven by strategic resource management in support of the INO-3107 program.
Earnings, Business Finance, Finance
Person-Based
Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INOVIO
Sign Up For FreeTo access detailed company insights
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; an... Read More
